European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Meta Expands AI Training With Employee Activity Tracking Tools 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
BOULDER, Colo., March 20, 2017 -- Dr. Jeffery Weber will present data from a collaboration in which proteomic tests developed by Biodesix® could help guide therapy choices in immuno-oncology. These blood-based tests, which were developed on Biodesix’s proprietary Diagnostic Cortex™ platform, may identify patients who derive significant benefit from anti-PD-1 monotherapy and might not gain additional benefit from the addition of anti-CTLA-4 agents. Dr. Weber will make his presentation at the 4th Immunotherapy of Cancer Conference in Europe (ITOC4).
Session Title: Proteomic Test Identifies Sensitivity and Resistance to Immunotherapy in Cancer Patients
Plenary Session Date/Time: Tuesday March 21, 4:50PM
Location: Prague Congress Center, 5 Kvetna 65, Prague, Czech Republic
About Jeffery Weber
Jeffrey S. Weber, MD, Ph.D, is the deputy director of the Perlmutter Cancer Center at New York University – Langone Medical Center, where he serves as a Professor in the Department of Medicine. Dr. Weber is co-director of the Center’s Melanoma Research Program.
About Biodesix
Biodesix® is a molecular diagnostics company advancing the development of innovative, multi-omic blood tests in oncology to enable precision medicine. Biodesix designs, develops and commercializes multivariate molecular liquid biopsy tests, including the GeneStrat® and VeriStrat® tests, that deliver results within 72 hours. The company is changing the standard of care by providing physicians with real-time clinical data at diagnosis with the Biodesix Lung Reflex™ testing strategy, for better therapeutic guidance, more accurate prognosis and enhanced disease monitoring to improve patient outcomes. At the forefront of personalized medicine, Biodesix is developing new tests to identify patients who may benefit from immunotherapies. In addition to developing novel clinical tests independently, the company partners with biotechnology and pharmaceutical companies to develop companion diagnostics for use with therapeutic agents.
For more information about Biodesix, please visit www.Biodesix.com.
Contact: Rachel Biederman 720-214-5774 [email protected]
